Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions
CRVS Stock Forecast
Corvus Pharmaceuticals stock forecast is as follows: an average price target of $9.50 (represents a 5.32% upside from CRVS’s last price of $9.02) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CRVS Price Target
CRVS Analyst Ratings
Corvus Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 22, 2024 | Graig Suvannavejh | Mizuho Securities | $12.00 | $7.56 | 58.73% | 33.04% |
Aug 18, 2023 | Jeff Jones | Oppenheimer | $7.00 | $2.19 | 219.65% | -22.39% |
Corvus Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 1 | 1 |
Avg Price Target | $12.00 | $12.00 | $12.00 |
Last Closing Price | $9.02 | $9.02 | $9.02 |
Upside/Downside | 33.04% | 33.04% | 33.04% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
May 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Aug 18, 2023 | Oppenheimer | - | Outperform | Initialise |
Corvus Pharmaceuticals Financial Forecast
Corvus Pharmaceuticals Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-8.96M | $-8.96M | $-8.36M | $-8.36M | $-7.02M | $-6.57M | $-6.87M |
High Forecast | $-8.96M | $-8.96M | $-8.36M | $-8.36M | $-7.02M | $-5.97M | $-6.87M |
Low Forecast | $-8.96M | $-8.96M | $-8.36M | $-8.36M | $-7.02M | $-6.57M | $-6.87M |
Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.12 | $-0.11 | $-0.12 |
High Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.12 | $-0.10 | $-0.12 |
Low Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.12 | $-0.11 | $-0.12 |
Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
CRVS | Corvus Pharmaceuticals | $9.02 | $9.50 | 5.32% | Buy |
HOOK | HOOKIPA Pharma | $3.76 | $3.00 | -20.21% | Buy |
CRVS Forecast FAQ
Is Corvus Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Corvus Pharmaceuticals (CRVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CRVS's total ratings.
What is CRVS's price target?
Corvus Pharmaceuticals (CRVS) average price target is $9.5 with a range of $7 to $12, implying a 5.32% from its last price of $9.02. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Corvus Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for CRVS stock, the company can go up by 5.32% (from the last price of $9.02 to the average price target of $9.5), up by 33.04% based on the highest stock price target, and down by -22.39% based on the lowest stock price target.
Can Corvus Pharmaceuticals stock reach $14?
CRVS's average twelve months analyst stock price target of $9.5 does not support the claim that Corvus Pharmaceuticals can reach $14 in the near future.
What is Corvus Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $12 price target for Corvus Pharmaceuticals (CRVS) this month, up 33.04% from its last price of $9.02. Compared to the last 3 and 12 months, the average price target increased by 33.04% and increased by 33.04%, respectively.
What are Corvus Pharmaceuticals's analysts' financial forecasts?
Corvus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-20.451M (high $-19.854M, low $-20.451M), average SG&A $0 (high $0, low $0), and average EPS is $-0.342 (high $-0.333, low $-0.342). CRVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.632M (high $-34.632M, low $-34.632M), average SG&A $0 (high $0, low $0), and average EPS is $-0.58 (high $-0.58, low $-0.58).